

Corrigendum

Corrigendum to: Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2

Shi-Bing Zhang^{a,b,1}, Ming Hong^{c,1}, Xiao-Yang Sun^a, Da Huang^a, Dan-Hua He^a, Yu-Fei Chen^a, Yong Yuan^{c,*} and Yong-Qiang Liu^{a,*}

^aKey Laboratory of Chinese Medicinal Resource from *Lingnan* (Guangzhou University of Chinese Medicine), Ministry of Education; Research Center of Chinese Herbal Resources Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

^bInstitute of Clinical Pharmacology, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

^cInstitute of Advanced Diagnostic and Clinical Medicine, Zhongshan People's Hospital, Zhongshan 528403, China

¹These authors contributed equally to this work: Shi-Bing Zhang, Ming Hong.

*Correspondence: liuyq@gzucm.edu.cn (Y.-Q. Liu); Yuyong1123@yahoo.com.cn (Y. Yuan)

DOI 10.15212/AMM-2023-1001

Corrigendum to: Shi-Bing Zhang, Ming Hong, Xiao-Yang Sun, Da Huang, Dan-Hua He, Yu-Fei Chen, Yong Yuan and Yong-Qiang Liu. 2022. Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2. *Acta Materia Medica*. Volume 1, Issue 3, pages 302–313. (DOI: 10.15212/AMM-2022-0011)

The authors regret that in **Figure 2c**, the image of SB (μM)-0 in the H1299 panel was inadvertently misused during the figure preparation. The correct images are shown below.

The authors would like to apologise for any inconvenience caused.




Figure 2 |